Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

137 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study.
Boyer M, Şendur MAN, Rodríguez-Abreu D, Park K, Lee DH, Çiçin I, Yumuk PF, Orlandi FJ, Leal TA, Molinier O, Soparattanapaisarn N, Langleben A, Califano R, Medgyasszay B, Hsia TC, Otterson GA, Xu L, Piperdi B, Samkari A, Reck M; KEYNOTE-598 Investigators. Boyer M, et al. Among authors: sendur man. J Clin Oncol. 2021 Jul 20;39(21):2327-2338. doi: 10.1200/JCO.20.03579. Epub 2021 Jan 29. J Clin Oncol. 2021. PMID: 33513313 Clinical Trial.
Neutrophil-lymphocyte ratio as a prognostic factor for survival in patients with advanced renal cell carcinoma (Turkish Oncology Group Study).
Hizal M, Sendur MA, Yasar HA, Bir Yucel K, Arslan C, Ucar G, Karakaya S, Taban H, Kucukarda A, Erturk I, Bilgin B, Yıldırım N, Demirci U, Kılıckap S, Cicin I, Karadurmus N, Yalcin B, Ürün Y. Hizal M, et al. J Oncol Pharm Pract. 2020 Oct;26(7):1583-1589. doi: 10.1177/1078155219900908. Epub 2020 Feb 13. J Oncol Pharm Pract. 2020. PMID: 32054412
A Phase II Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab and Chemoradiotherapy in the Adjuvant Setting in Operated Patients With HER2-positive Gastric or Gastroesophageal Junction Cancer (TOXAG Study): A Turkish Oncology Group Study.
Abali H, Yalcin S, Onal HC, Dane F, Oksuzoglu B, Ozdemir N, Mertsoylu H, Artac M, Camci C, Karabulut B, Basal FB, Budakoglu B, Sendur MAN, Goktas B, Ozdener F, Baygul A. Abali H, et al. Among authors: sendur man. Am J Clin Oncol. 2021 Jul 1;44(7):301-307. doi: 10.1097/COC.0000000000000825. Am J Clin Oncol. 2021. PMID: 33979100 Clinical Trial.
Pertuzumab in HER2-positive breast cancer.
Sendur MA, Aksoy S, Altundag K. Sendur MA, et al. Curr Med Res Opin. 2012 Oct;28(10):1709-16. doi: 10.1185/03007995.2012.728132. Epub 2012 Oct 11. Curr Med Res Opin. 2012. PMID: 22953713 Review.
Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer.
Boyraz B, Sendur MA, Aksoy S, Babacan T, Roach EC, Kizilarslanoglu MC, Petekkaya I, Altundag K. Boyraz B, et al. Curr Med Res Opin. 2013 Apr;29(4):405-14. doi: 10.1185/03007995.2013.775113. Epub 2013 Mar 1. Curr Med Res Opin. 2013. PMID: 23402224 Review.
Everolimus: a new hope for patients with breast cancer.
Sendur MA, Zengin N, Aksoy S, Altundag K. Sendur MA, et al. Curr Med Res Opin. 2014 Jan;30(1):75-87. doi: 10.1185/03007995.2013.846253. Epub 2013 Oct 14. Curr Med Res Opin. 2014. PMID: 24050600 Review.
137 results